Immunovant(IMVT) - 2022 Q4 - Earnings Call Presentation

IMMUNOVANT | --- | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | Phase 3 Development for Batoclimab in Thyroid Eye Disease | | | | | | Investor Presentation June 8, 2022 | | | | | Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such ...